氧合酶-2抑制剂celecoxib与喜树碱类衍生物联合用药的实验研究
http://www.100md.com
付剑江, 李 燕, 李洪燕, 刘 悦, 陈晓光
细胞凋亡;细胞周期;环氧合酶-2;拓扑异构酶Ⅰ抑制剂;结肠癌;腹泻,付剑江,李燕,李洪燕,刘悦,陈晓光,通讯作者,:,Effe
 |
| 第4页 |
 |
| 第1页 |
参见附件(1054KB，7页)。
付剑江,李燕,李洪燕, 刘悦,陈晓光,中国医学科学院、中国协和医科大学药物研究所药理室 北京市 100050
付剑江,1975-09-06生, 江西省丰城市人, 汉族,博士研究生, 从事肿瘤药理学研究.
通讯作者:陈晓光,100050, 北京市宣武区先农坛街1号,中国医学科学院、中国协和医科大学药物研究所药理室. chxg@imm.ac.cn
电话: 010-63165207 传真:010-63017757
收稿日期:2005-07-11 接受日期:2005-07-20
Effects of the combination of topoisomerase I inhibitors and celecoxib,a selective cylooxygenase-2 inhibitor on colorectal cancer
Jian-Jiang Fu, Yan Li, Hong-Yan Li, Yue Liu, Xiao-Guang Chen
Jian-Jiang Fu, Yan Li, Hong-Yan Li, Yue Liu, Xiao-Guang Chen, Departmentof Pharmacology, Institute of Materia Medica, Chinese Academy of MedicalSciences and Peking Union Medical College, Beijing 100050, China
Correspondence to: Xiao-Guang Chen, Department of Pharmacology,Institute of Materia Medica, Chinese Academy of Medical Sciences andPeking Union Medical College, 1 Xiannongtan Street, Beijing 100050, China. chxg@imm.ac.cn
Received: 2005-07-11 Accepted: 2005-07-20
Abstract
AIM: To investigate the antitumor properties of camptothecins (CPTs)combined with celecoxib, a selective cylooxygenase-2 (COX-2) inhibitor, invitro and in vivo, and the effects of celecoxib on irinotecan(CPT-11)-induced diarrhea in mice.
METHODS: Four human colon cancer cell lines, HT-29, HCT-8, HCT-116and Caco-2 were exposed to the increasing concentrations (10-5,10-4,10-3,10-2,10-1,1, 10,100 mmol/L)of three topoisomerase I (Topo I) inhibitors, CPT-11, CPT and topotecan (TPT),and celecoxib (1 and 5 mmol/L)as well as a combination of each Topo I inhibitor. Then MTT assay wasperformed to evaluate the effects of adjunct use of celecoxib on thechemosensitivity of colon cancer cells to CPTs. HT-29 cells were dividedinto control group, celecoxib treatment group, CPT treatment group andcombined CPT with celecoxib treatment group. Flow cytometry was used toevaluate the apoptotic rates and cell cycle distribution ......
您现在查看是摘要介绍页，详见PDF附件(1054KB，7页)。